BMY
New deal, bigger pipeline
Bristol Myers Squibb is back in the deal-making chair. On May 12th, the company said it struck global strategic collaboration and license agreements with Hengrui Pharma to advance 13 early-stage programs spanning oncology, hematology, and immunology.
That’s corporate-speak for: BMS is trying to stack more cards on the table before the next hand is dealt. Early-stage programs are risky — some will fizzle, some will shine, and some will just politely disappear into the biotech void — but the upside is obvious if even a couple turn into meaningful drugs.
Why investors should care
This isn’t a clean, near-term revenue pop. It’s more of a long-game move, the pharmaceutical version of planting trees you probably won’t sit under until later. But it matters because pipeline depth is everything in Big Pharma. More programs can mean:
- more optionality if current products start to age out
- more shots at future revenue
- less dependence on any single therapy to carry the company
The takeaway
BMS is still playing the classic Big Pharma game: pay for access, spread the risk, and hope the science does the rest. If these 13 programs pan out, today’s partnership could look like a sneaky good growth move. If not, well, that’s the price of buying lottery tickets with lab coats.
Big picture: BMS is trying to stay relevant in a pipeline race where standing still is basically moving backward.